PTSD is a severe psychiatric illness characterised by four core symptom clusters: re-experiencing, avoidance, negative cognition and mood and hyperarousal.1 With an estimated
lifetime prevalence in community samples of up to 8 %, PTSD results in a great deal of personal suffering and escalating social and
economic costs.2 Unfortunately, current evidence - based treatments for PTSD leave a high percentage with a significant symptom
burden, highlighting the urgent need for novel treatments.